Understanding cardiovascular pharmacology is vital for evidence-based, safe, and effective treatment. At the World Cardiology Conference (WCC 2026), this session will review current and emerging drugs for hypertension, heart failure, lipid disorders, arrhythmias, and thrombosis. Topics include pharmacogenomics, drug-drug interactions in polypharmacy, and the role of SGLT2 inhibitors and GLP-1 agonists in cardio-metabolic care. Clinical trial data and real-world effectiveness studies will provide insights into optimal therapy selection.